EIKN
Eikon Therapeutics·NASDAQ
--
--(--)
--
--(--)
EIKN fundamentals
During Q4 2025, Eikon Therapeutics (EIKN) reported revenue of --, a YoY change of 0.00%. Net income was -79.66M, a YoY change of -22.69%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2024 | Q4,2025 | TTM |
|---|
Start Date | Oct 1, 2024 | Oct 1, 2025 | -- |
End Date | Dec 31, 2024 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | -- |
Pretax Income From Continuing Operations | -64.92M -- | -79.66M -22.69% | -- -- |
Net Income | -64.92M -- | -79.66M -22.69% | -- -- |
Total Comprehensive Income | -64.92M -- | 244.59M +476.74% | -- -- |
You can ask Aime
What factors drove the changes in Eikon Therapeutics's revenue and profit?What does Eikon Therapeutics do and what are its main business segments?What guidance did Eikon Therapeutics's management provide for the next earnings period?What were the key takeaways from Eikon Therapeutics's earnings call?What is the revenue and EPS growth rate for Eikon Therapeutics year over year?Did Eikon Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Eikon Therapeutics’s earnings call?What is Eikon Therapeutics's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
